Serina Therapeutics to Sell Up to $25 Million in Stock to Roth Principal Investments
Serina Therapeutics entered into a Common Stock Purchase Agreement and a Registration Rights Agreement with Roth Principal Investments, both dated August 21, 2026. The company can choose, at its sole discretion, to sell up to $25 million of newly issued common stock over up to 36 months, so the deal gives it a funding option while adding potential dilution at prices set below market.
Key points
- Agreement dated August 21, 2026 allows the company to sell up to $25 million of newly issued common stock to Roth Principal Investments, at the company's option and with no obligation to sell.
- Purchases are priced at a discount to volume weighted average price: 7% before cumulative sales reach $12.5 million and 3% after, for market open and intraday purchases.
- Under NYSE American rules, issuance is capped at 5,077,554 shares, equal to 19.99% of shares outstanding before signing, unless stockholders approve more or other conditions are met.
- Sales can begin only after a resale registration statement is declared effective by the SEC, and the company may direct purchases for up to 36 months from that Commencement Date.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 26, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.